CLINICAL_TRIALS
trial_result
· 2015-03-19
Clinical Trial Update: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]
Summary
This update reports safety and tolerability results from a Phase 3 trial of fingolimod in patients with relapsing-remitting multiple sclerosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2015-03-19